6 Previous meta-analysis suggested that hematologic malignancies were more likely to occur in patients with IBD, but the result showed borderline significance. 7 For specific types of hematologic malignancies, the results of research vary and deserve further analysis and exploration. 8 In addition, with the development of research, the therapeutic agents of IBD have changed, and more and more biologics have been adopted.
← all excerpts
Risk of Hematologic Malignancies in Patients with Inflammatory Bowel Disease: A Meta-Analysis of Cohort Studies.
1
—
—